Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil

Pseudomonas aeruginosa, an opportunistic pathogen causing infections in immunocompromised patients, usually shows pronounced antimicrobial resistance. In recent years, the frequency of carbapenemases P. aeruginosa has decreased, which allows use new beta-lactams/combinations therapy. Therefore, vitro evaluation these drugs contemporary isolates is warranted. We evaluated susceptibility and genomic aspects 119 clinical from 24 different hospitals Brazil 2021–2022. Identification was performed via MALDI-TOF-MS, identified through broth microdilution, gradient tests, or disk diffusion. Whole-genome sequencing carried out using NextSeq equipment. The most active drug cefiderocol (100%), followed by ceftazidime–avibactam (94.1%), ceftolozane–tazobactam (92.4%), imipenem–relebactam (81.5%). Imipenem detected 59 (49.6%), aminoglycoside tobramycin, to 99 (83.2%) were susceptible. Seventy-one sequence types (STs) detected, including twelve STs described herein. acquired resistance genes blaCTX-M-2 blaKPC-2 ten (8.4%) two (1.7%) isolates, respectively. Several virulence (exoSTUY, toxA, aprA, lasA/B, plcH) also identified. found that antimicrobials are effective against diverse population been circulating Brazilian years.